A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status.
Evan Hersh
Research Funding - Celgene
Michele Del Vecchio
Research Funding - Bristol-Myers Squibb; Celgene; Novartis; Roche
Michael Paul Brown
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Richard Kefford
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Carmen Loquai
Consultant or Advisory Role - Celgene
Alessandro Testori
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Mingyu Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene (B)
Ileana Elias
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Markus F. Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche